Q1 2023 Takeda Pharmaceutical Co Ltd Earnings Call Transcript
[Interpreted] Good evening, everybody, or good morning, everybody. Thank you very much for joining Takeda's earnings conference call webinar for the first quarter FY 2022. I will serve as MC today. My name is Ayako Iwamuro, in charge of Global IR.
First, I will explain language setup. (Operator Instructions)
Before starting, I'd like to remind everyone that we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today.
The factors that could cause our actual results to differ materially are discussed in our most recent Form 20-F and in other SEC filings of Takeda. Please also refer to the important notice on Page 2 of the presentation.
Let's move to the presentation today. We have with us Christophe Weber, President and CEO; R&D President, Andy Plump; and Chief Financial Officer, Constantine Saroukos. They will be presenting. After the presentation, we
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |